The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Iyer, SwaminathanSwaminathanIyerTruemper, LorenzLorenzTruemperO’Connor, Owen A.Owen A.O’ConnorPro, BarbaraBarbaraProIllidge, TimTimIllidgeAdvani, RanjanaRanjanaAdvaniBartlett, Nancy L.Nancy L.BartlettChristensen, Jacob HaaberJacob HaaberChristensenMorschhauser, FranckFranckMorschhauserDomingo-Domenech, EvaEvaDomingo-DomenechRossi, GiuseppeGiuseppeRossiKim, Won SeogWon SeogKimFeldman, TatyanaTatyanaFeldmanMenne, TobiasTobiasMenneBelada, DavidDavidBeladaIlles, ArpadArpadIllesTobinai, KenseiKenseiTobinaiTsukasaki, KunihiroKunihiroTsukasakiYeh, Su-PengSu-PengYehShustov, AndreiAndreiShustovHuettmann, AndreasAndreasHuettmannSavage, Kerry J.Kerry J.SavageYuen, SamSamYuenZinzani, Pier LuigiPier LuigiZinzaniMiao, HarryHarryMiaoBunn, VeronicaVeronicaBunnFenton, KeenanKeenanFentonFanale, MichelleMichelleFanalePuhlmann, MarkusMarkusPuhlmannHorwitz, StevenStevenHorwitz2021-10-012021-10-012021https://resolver.sub.uni-goettingen.de/purl?gro-2/90186The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphomajournal_article000691910500363